{"id":29222,"date":"2016-12-22T17:53:59","date_gmt":"2016-12-22T16:53:59","guid":{"rendered":"http:\/\/www.fedaiisf.it\/?p=29222"},"modified":"2017-01-03T13:29:01","modified_gmt":"2017-01-03T12:29:01","slug":"ricerca-sviluppo-big-pharma-roi-si-ferma-al-37-cento","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/ricerca-sviluppo-big-pharma-roi-si-ferma-al-37-cento\/","title":{"rendered":"Research and Development: for Big Pharma the ROI stops at 3.7 percent"},"content":{"rendered":"<p>3.7%. This is the expected percentage of the return on R&amp;D investments made by major pharmaceutical companies. Almost seven percentage points less than the figure <img loading=\"lazy\" decoding=\"async\" class=\"alignright\" src=\"https:\/\/www2.deloitte.com\/content\/dam\/Deloitte\/us\/Images\/Misc\/Infographics\/us-measuring-return-on-pharma-innovation-2016.jpg\" width=\"627\" height=\"3020\" \/><em>monster\u00a0<\/em>of 10.1% reached in 2010. This is underlined by the report drawn up, like every year, by the Center for Health Solutions of the company services company Deloitte.<\/p>\n<p>A slight increase in the number of active substances pending approval might actually suggest that things are improving, but the trend continues to be downwards. In addition, the cost of developing a drug has increased from an average of $1.2 billion to $1.54 billion, and it takes pharmaceutical companies 14 years of work to launch a new product.<\/p>\n<p>The same decline also for medium-sized companies, whose returns on investments fell from 17.4% in 2013 to 9.9% this year. According to Colin Terry, Deloitte&#039;s industry partner <em>life sciences,<\/em> the problem is that companies are no longer able to sell new products at the prices imposed in the past. Average peak sales for new launches would have dropped from $816 million in 2010 to $394 million this year, a decline by more than 11% year-over-year.<\/p>\n<p>And the number of FDA approvals is also down. One way to improve R&amp;D yields would be to focus on a few specific diseases. A trend already adopted by several large pharmaceutical companies that are discontinuing units, such as GlaxoSmithKline which has sold anticancer products to take Novartis vaccines. Larger companies, which have lower returns on investment than smaller companies, should therefore be more agile and flexible.<\/p>\n<p><a href=\"http:\/\/www.dailyhealthindustry.it\/ricerca-e-sviluppo-roi-ancora-in-calo-big-pharma-si-ferma-al-37-per-cento-ID4085.html\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #0000ff;\">December 16, 2016 \u2013 Daily Health Industry<\/span><\/a><\/p>\n<p>Related news:\u00a0<a href=\"https:\/\/www2.deloitte.com\/us\/en\/pages\/life-sciences-and-health-care\/articles\/measuring-return-from-pharmaceutical-innovation.html\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #0000ff;\">Measuring the return from pharmaceutical innovation 2016<\/span><\/a><\/p>\n<ul class=\"inline-nav-content-page\">\n<li><a class=\"inline-nav-container-links body-copy\" href=\"https:\/\/www2.deloitte.com\/us\/en\/pages\/life-sciences-and-health-care\/articles\/measuring-return-from-pharmaceutical-innovation.html#1\" target=\"_blank\" rel=\"noopener\">View or download the report<\/a><\/li>\n<li><a class=\"inline-nav-container-links body-copy\" href=\"https:\/\/www2.deloitte.com\/us\/en\/pages\/life-sciences-and-health-care\/articles\/measuring-return-from-pharmaceutical-innovation.html#2\" target=\"_blank\" rel=\"noopener\">Access the methodology<\/a><\/li>\n<li><a class=\"inline-nav-container-links body-copy\" href=\"https:\/\/www2.deloitte.com\/us\/en\/pages\/life-sciences-and-health-care\/articles\/measuring-return-from-pharmaceutical-innovation.html#3\" target=\"_blank\" rel=\"noopener\">View the infographic<\/a><\/li>\n<li><a class=\"inline-nav-container-links body-copy\" href=\"https:\/\/www2.deloitte.com\/us\/en\/pages\/life-sciences-and-health-care\/articles\/measuring-return-from-pharmaceutical-innovation.html#4\" target=\"_blank\" rel=\"noopener\">Access prior year&#039;s reports<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>3,7%. \u00c8 questa la percentuale prevista del\u00a0ritorno sugli investimenti in ricerca e sviluppo fatti dalle maggiori aziende farmaceutiche. Quasi sette punti percentuali in meno rispetto alla cifra monstre\u00a0del 10,1%\u00a0raggiunta nel 2010. A sottolinearlo \u00e8 il rapporto stilato, come ogni anno, dal Centre for Health Solutions della societ\u00e0 di servizi per le imprese Deloitte. Un leggero &hellip;<\/p>","protected":false},"author":4,"featured_media":29226,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-29222","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/29222","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=29222"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/29222\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/29226"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=29222"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=29222"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=29222"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}